Regeneron Lifts Stake In Biotech Partner ISA Pharma
Equity Injection Part Of €26m Funding To Advance ISA’s Pipeline
Armed with €26m in fresh funds from investors that include partner Regeneron, ISA Pharma can now advance promising preclinical assets generated from its proprietary platform, containing a mix of synthetic antigenic peptides, its CEO tells Scrip.
